Evolocumab Market

Evolocumab(trade name Repatha) is a monoclonal antibody medication designed for the treatment of hyperlipidemia.
Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and its inhibition thereby enhances the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.
Evolocumab Market contains market size and forecasts of Evolocumab in global, including the following market information:
Global Evolocumab Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Evolocumab Market Sales, 2017-2022, 2023-2028, (Kg)
Global top five Evolocumab companies in 2021 (%)
The global Evolocumab market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Patent Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Evolocumab include BOCSCI, Carbosynth, TargetMol Chemicals, Chemren Bio-Engineering, DC Chemicals, Hefei Enli Medical Technology, Hefei Hirisun Pharmatech, Hubei Kele Fine Chemical and Hubei Xingcheng Biotechnology, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Evolocumab manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Evolocumab Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Evolocumab Market Segment Percentages, by Type, 2021 (%)
Patent
Generic
Global Evolocumab Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Evolocumab Market Segment Percentages, by Application, 2021 (%)
Chemical
Pharmaceutical
Global Evolocumab Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Evolocumab Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Evolocumab revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Evolocumab revenues share in global market, 2021 (%)
Key companies Evolocumab sales in global market, 2017-2022 (Estimated), (Kg)
Key companies Evolocumab sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
BOCSCI
Carbosynth
TargetMol Chemicals
Chemren Bio-Engineering
DC Chemicals
Hefei Enli Medical Technology
Hefei Hirisun Pharmatech
Hubei Kele Fine Chemical
Hubei Xingcheng Biotechnology
Hubei Zhongshan Medical Technology
Nantong Feiyu Biological Technology
Nantong Hi-Future Biotechnology
Shanghai Biochempartner
Shanghai Loulan Biotechnology
Shanghai Macklin Biochemical
Shanghai Minkai Biotechnology
Shanghai Ruihui Chemical Technology
Shanghai Yifei Biotechnology
Sichuan Weiqi Biotechnology
Taizhou KEDE Chemical
Taizhou Kerui Bio-Technology
WeiShi Reagent
Wuhan Fortuna Chemical
Wuhan Sunrise Technology Development
Wuhan Weisman Bioengineering
Wuhan Yingnuo Pharmaceutical Technology